NASDAQ:SBBP - Strongbridge Biopharma Stock Price, Forecast & News

Strongbridge Biopharma trades on the NASDAQ under the ticker symbol "SBBP."

Strongbridge Biopharma plc (NASDAQ:SBBP) announced its quarterly earnings data on Thursday, November, 7th. The biotechnology company reported ($0.25) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.32) by $0.07. The biotechnology company earned $5.68 million during the quarter, compared to analyst estimates of $5.06 million. Strongbridge Biopharma had a net margin of 211.37% and a return on equity of 45.77%. View Strongbridge Biopharma's Earnings History.

Strongbridge Biopharma is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Strongbridge Biopharma.

Strongbridge Biopharma will be holding an earnings conference call on Tuesday, February 25th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Strongbridge Biopharma updated its FY 2019 Pre-Market earnings guidance on Monday, November, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $$18-20 million, compared to the consensus revenue estimate of $$20.82 million.

5 brokers have issued 12 month price objectives for Strongbridge Biopharma's shares. Their forecasts range from $8.00 to $18.00. On average, they expect Strongbridge Biopharma's share price to reach $13.25 in the next year. This suggests a possible upside of 285.2% from the stock's current price. View Analyst Price Targets for Strongbridge Biopharma.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Strongbridge Biopharma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Strongbridge Biopharma.

News articles about SBBP stock have been trending somewhat positive this week, according to InfoTrie Sentiment. The research group scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Strongbridge Biopharma earned a news impact score of 1.3 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Strongbridge Biopharma.

Strongbridge Biopharma saw a drop in short interest during the month of January. As of January 31st, there was short interest totalling 393,800 shares, a drop of 24.1% from the January 15th total of 518,500 shares. Based on an average trading volume of 496,800 shares, the days-to-cover ratio is currently 0.8 days. Currently, 1.2% of the company's stock are short sold. View Strongbridge Biopharma's Current Options Chain.

Some companies that are related to Strongbridge Biopharma include ANI Pharmaceuticals (ANIP), BioXcel Therapeutics (BTAI), Provention Bio (PRVB), DiaMedica Therapeutics (DMCAF), Frequency Therapeutics (FREQ), Retrophin (RTRX), G1 Therapeutics (GTHX), Eagle Pharmaceuticals (EGRX), Arcus Biosciences (RCUS), Vanda Pharmaceuticals (VNDA), Aprea Therapeutics (APRE), Cara Therapeutics (CARA), RAPT Therapeutics (RAPT), Akero Therapeutics (AKRO) and Omeros (OMER).

Based on aggregate information from My MarketBeat watchlists, some companies that other Strongbridge Biopharma investors own include Genocea Biosciences (GNCA), Energy Transfer LP Unit (ET), SCYNEXIS (SCYX), Agile Therapeutics (AGRX), Dicerna Pharmaceuticals (DRNA), Opko Health (OPK), Viking Therapeutics (VKTX), Abeona Therapeutics (ABEO), Sorrento Therapeutics (SRNE) and VBI Vaccines (VBIV).

Strongbridge Biopharma's stock is owned by a number of of retail and institutional investors. Top institutional investors include State Street Corp (1.25%), Point72 Asset Management L.P. (1.20%), Renaissance Technologies LLC (1.18%), Geode Capital Management LLC (0.73%), Diversified Trust Co (0.37%) and Alambic Investment Management L.P. (0.22%). View Institutional Ownership Trends for Strongbridge Biopharma.

SBBP stock was sold by a variety of institutional investors in the last quarter, including Private Advisors LLC and Tredje AP fonden. View Insider Buying and Selling for Strongbridge Biopharma.

SBBP stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Diversified Trust Co, Point72 Asset Management L.P., Alambic Investment Management L.P., Bank of Montreal Can, Geode Capital Management LLC, State Street Corp and Acadian Asset Management LLC. View Insider Buying and Selling for Strongbridge Biopharma.

Shares of SBBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SBBP stock can currently be purchased for approximately $3.44.

Strongbridge Biopharma has a market capitalization of $186.48 million and generates $18.03 million in revenue each year. The biotechnology company earns $31.85 million in net income (profit) each year or $0.31 on an earnings per share basis. Strongbridge Biopharma employs 106 workers across the globe.View Additional Information About Strongbridge Biopharma.

The official website for Strongbridge Biopharma is http://www.strongbridgebio.com/.

Strongbridge Biopharma's mailing address is 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053. The biotechnology company can be reached via phone at 610-254-9200 or via email at [email protected]